Cormorant Asset Management, an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles, led a $150m Series B funding round in Rapport Therapeutics, a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, with participation from Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital, T. Rowe Price Associates, Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation. “We are appreciative for the support of such a prominent group of new investors and excited to welcome Ray and Jim to our board of directors. Rapport is extremely well positioned to advance our ongoing clinical programs in seizure and psychiatric disorders, and to expand our pipeline by harnessing our unique capability to leverage receptor-associated proteins for precision neuromedicine. We are poised for tremendous growth and look forward to pursuing a wide variety of opportunities to serve patients who desperately need more effective treatments,” Abraham Ceesay, Rapport Therapeutics CEO.